Document is current
Any future updates will be listed below
-
Authors
Skinner, MW. https://orcid.org/0000-0002-0934-0680
Chai-Adisaksopha, C.
Curtis, R.
Frick, N.
Nichol, M.
Noone, D.
O’Mahony, B.
Page, D.
Stonebraker, J. S.
Iorio, A.
-
Funding
Funding for this research was provided by:
Baxalta
Bayer
Bioverativ
Novo Nordisk
Sobi
Roache
-
More Information
Article History
Received: 9 July 2017
Accepted: 19 February 2018
First Online: 27 February 2018
Ethics approval and consent to participate
: Approval from the institutional review board or ethics committee was obtained. A participant description and disclaimer was provided with each questionnaire, and then, the participants were invited to proceed if they agreed or have an opportunity to ask questions. No identifiable patient information was disclosed as part of the study.
: Not applicable.
: CC has no potential conflict of interest. AI received grants from Baxalta now part of Shire, Bayer, Bioverativ, Sobi, Novo Nordisk and Roche. AI received non-financial support from US National Hemophilia Foundation. RC received grants from Baxalta now part of Shire, Bayer, Bioverativ, Sobi, Novo Nordisk and Roche. RC received non-financial support from US National Hemophilia Foundation. MN received grants from Bayer, Pfizer, Genentech, Biogen, Novo Nordisk, Baxter and CSL Behring. MN received personal fees from Bayer and Biogen. DN received grants from Baxalta now part of Shire, Bayer, Bioverativ, Sobi, Novo Nordisk and Roche. DN also received non-financial support from US National Hemophilia Foundation. BOM received grants from Baxalta now part of Shire, Bayer, Bioverativ, Sobi, Novo Nordisk and Roche. BOM received non-financial support from US National Hemophilia Foundation. MS received grants from Baxalta now part of Shire, Bayer, Bioverativ, Sobi, Novo Nordisk and Roche. MS also received non-financial support from US National Hemophilia Foundation.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
